Last reviewed · How we verify
AARXION ANDA HLDING — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Capozide 25/15 | CAPTOPRIL | marketed | Thiazide Diuretic [EPC] | Renin | Metabolic | 1981-01-01 |
Therapeutic area mix
- Metabolic · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- · 1 shared drug class
- Cosette · 1 shared drug class
- Daiichi Sankyo · 1 shared drug class
- Direct_Rx · 1 shared drug class
- Generic (originally Merck) · 1 shared drug class
- Generic (originally Merck/AstraZeneca) · 1 shared drug class
- Roxane Laboratories · 1 shared drug class
- Takeda · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AARXION ANDA HLDING:
- AARXION ANDA HLDING pipeline updates — RSS
- AARXION ANDA HLDING pipeline updates — Atom
- AARXION ANDA HLDING pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AARXION ANDA HLDING — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aarxion-anda-hlding. Accessed 2026-06-10.